Gingival diseases - Non dental biofilm induced
Genetic/developmental disorders
Specific infections
Inflammatory and immune conditions
Reactive processes
Neoplasms
Endocrine, nutritional and metabolic
Traumatic lesions
Gingival pigmentation.Periodontitis

Necrotizing periodontal diseases
Necrotizing Gingivitis
Necrotizing Periodontitis
Necrotizing Stomatitis
Periodontitis as a manifestation of systemic disease
PeriodontitisOther conditions affecting the periodontium
(Periodontal Manifestations of Systemic Diseases and Developmental and Acquired Conditions)

Systemic disease of conditions affecting the periodontal support tissues
Other Periodontal Conditions
Periodontal abscesses
Endodontic- periodontal lesions
Mucogingival deformities and conditions
Gingival Phenotype
Gingival/Soft Tissue Recession
Lack of Gingiva
Decreased Vestibular Depth
Aberrant Frenum/muscle position
Gingival Excess
Abnormal Color
Condition of the exposed root surface
Traumatic occlusal forces
Primary Occlusal Trauma
Secondary Occlusal Trauma
Tooth and prosthesis related factors
Localized tooth-related factors
Localized dental prostheses-related factorsPeri-implant diseases and conditions

Peri-implant health
Peri-implant mucositis
Peri-implantitis
Peri-implant soft and hard tissue deficiencies

Staging
The goals of staging periodontitis is to classify the severity of damage and assess specific factors that may affect management.According to the 2017 classification, periodontitis is divided into four stages; after considering a few factors such as:

Amount and percentage bone loss radiographically
Clinical attachment loss, probing depth
Presence of furcation
Vertical bony defects
History of tooth loss related to periodontitis
Tooth hypermobility due to secondary occlusal trauma

Grading
According to the 2017 classification, the grading system for periodontitis consists of three grades:
Grade A: Slow progression of disease; no evidence of bone loss over last five years
Grade B: Moderate progression; < 2mm of bone loss over last five years
Grade C: Rapid progression or future progression at high risk; ≥ 2mm bone loss over five yearsRisk factors affecting which grade a person is classified into include:
Smoking
Diabetes

Prevention
Daily oral hygiene measures to prevent periodontal disease include:

Brushing properly on a regular basis (at least twice daily), with the person attempting to direct the toothbrush bristles underneath the gumline, helps disrupt the bacterial-mycotic growth and formation of subgingival plaque.
Burosumab, sold under the brand name Crysvita, is a human monoclonal antibody medication for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia. Burosumab was approved by the FDA for its intended purpose, in patients aged one year and older, in April 2018. The FDA approval fell under both the breakthrough therapy and orphan drug designations. It was approved for use in the European Union in February 2018.The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Medical uses
In the United States, burosumab is indicated for the treatment of adults and children ages one year and older with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets, and for the treatment of people age two and older with tumor-induced osteomalacia (TIO), a rare disease that is characterized by the development of tumors that cause weakened and softened bones. The tumors associated with TIO release a peptide hormone-like substance known as fibroblast growth factor 23 (FGF23) that lowers phosphate levels.In the European Union, burosumab is indicated for the treatment of X-linked hypophosphataemia with radiographic evidence of bone disease in children one year of age and older and adolescents with growing skeletons.XLH is genetic disorder affecting phosphate metabolism within the body, which results in hypophosphatemia. The disease is characterized by overproduction of the FGF23 hormone in bone cells. The FGF23 hormone is responsible for blocking phosphate re-absorption by the kidney and the suppression of the vitamin D dependent phosphate absorption by the intestine.